Identification of reactive intermediate formation and bioactivation pathways in Abemaciclib metabolism by LC–MS/MS: in vitro metabolic investigation

Abemaciclib (Verzenio(®)) is approved as a tyrosine kinase inhibitor (TKI) for breast cancer treatment. In this study, in vitro phase I metabolic profiling of Abemaciclib (ABC) was done using rat liver microsomes (RLMs). We checked the formation of reactive intermediates in ABC metabolism using RLMs...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadi, Adnan A., Darwish, Hany W., Abuelizz, Hatem A., Alsubi, Thamer A., Attwa, Mohamed W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society 2019
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366225/
https://www.ncbi.nlm.nih.gov/pubmed/30800400
http://dx.doi.org/10.1098/rsos.181714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366225/
https://www.ncbi.nlm.nih.gov/pubmed/30800400
http://dx.doi.org/10.1098/rsos.181714

Ejemplares similares